VITAL: Real-World Evaluation of Amlodipine/Valsartan. (VITAL)

September 24, 2026 updated by: VIVA PHARM LLP

Evaluation of Clinical Effectiveness in Real-World Clinical Practice, as Well as the Safety and Adherence to Therapy With a Fixed-Dose Combination of Amlodipine and Valsartan

The goal of this observational study is to evaluate the effectiveness, safety, and treatment adherence of a fixed-dose combination of amlodipine and valsartan in adults with grade 2-3 hypertension in real-world clinical practice in Kazakhstan. The study will include patients who have already been prescribed the fixed-dose combination of amlodipine and valsartan (Agvistat®) by their treating physician as part of routine medical care, independently of their participation in the study.

The main questions it aims to answer are:

What proportion of participants achieve the target blood pressure after 12 weeks of treatment with the fixed-dose combination of amlodipine and valsartan? How well do participants adhere to treatment, and what patient characteristics are associated with treatment adherence? What changes occur in blood pressure, heart rate, quality of life, and selected laboratory measures during the 12-week observation period? What adverse events occur during treatment?

Participants will:

Have their clinical and demographic information and data from routine medical care recorded during the study.

Have blood pressure, heart rate, and other relevant clinical data assessed during the 12-week observation period.

Complete questionnaires assessing treatment adherence and quality of life. Participate in follow-up visits at 4, 8, and 12 weeks; the 4- and 8-week visits will be conducted remotely, while the enrollment and 12-week visits will be conducted at the study site.

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

216

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Kazakhstan
      • Aktobe, Kazakhstan
        • 'Kuanysh' LLP Health Centre
      • Aktobe, Kazakhstan
        • 'Phoenix Hospital' LLP
      • Aktobe, Kazakhstan
        • Sara Clinic Medical Centre LLP
      • Almaty, Kazakhstan
        • "Medical Assistance Group" LLP
      • Almaty, Kazakhstan
        • 'Vector Vita' Medical Centre LLP
      • Almaty, Kazakhstan
        • State-owned Enterprise for Public Health 'National Hospital of the Medical Centre of the Presidential Administration of the Republic of Kazakhstan'
      • Astana, Kazakhstan
        • "Green Clinic" LLP
      • Astana, Kazakhstan
        • "Kazakhstan Social and Medical Company 'ZHANYA' LLP"
      • Astana, Kazakhstan
        • State-owned Enterprise 'Hospital of the Medical Centre of the Presidential Administration of the Republic of Kazakhstan'
      • Shymkent, Kazakhstan
        • "Clinic DL-ECO" LLP
      • Shymkent, Kazakhstan
        • "Esculap-Vita" LLP
      • Shymkent, Kazakhstan
        • "OrkenMed" LLP
      • Shymkent, Kazakhstan
        • 'Ai-Nury' Medical Centre LLP
      • Ust-Kamenogorsk, Kazakhstan
        • 'GaMMA' Clinical and Diagnostic Centre LLP
      • Ust-Kamenogorsk, Kazakhstan
        • State Communal Enterprise on the Right of Economic Management "East Kazakhstan Regional Hospital
      • Ust-Kamenogorsk, Kazakhstan
        • The 'Outpatient Centre' organisation
    • Turkistan Oblast
      • Shymkent, Turkistan Oblast, Kazakhstan
        • "Medical Center Shubarsu" LLP
      • Turkestan, Turkistan Oblast, Kazakhstan
        • "Clinic of Doctor Irsaliev N.R." LLP

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

The study population will consist of adult male and female patients aged ≥18 years with a confirmed diagnosis of grade 2-3 hypertension who have been prescribed a fixed-dose combination of amlodipine and valsartan (Agvistat®) by their treating physician as part of standard clinical practice, independently of participation in the study. The study will include patients with a medical history indicating failure to achieve target blood pressure while receiving a free combination of antihypertensive drugs. A total of 216 participants will be enrolled and observed for up to 12 weeks.

Description

Inclusion Criteria:

  1. Male or female participants aged ≥18 years at the time of enrollment.
  2. Signed and dated written informed consent in accordance with ICH GCP and applicable local legislation before enrollment in the study.
  3. Women of childbearing potential must use an adequate method of contraception throughout the study.
  4. Documented diagnosis of grade 2-3 hypertension according to current clinical guidelines for hypertension, defined as systolic blood pressure (SBP) ≥140 mmHg and/or diastolic blood pressure (DBP) ≥90 mmHg measured at two different visits.
  5. Treatment with a fixed-dose combination of amlodipine and valsartan (Agvistat®) prescribed by the treating physician as part of standard clinical practice before enrollment, independently of participation in this study.
  6. Medical history indicating failure to achieve target blood pressure while receiving a free combination of antihypertensive drugs.

Exclusion Criteria:

  1. Participation in any randomized controlled trial within 3 months before enrollment in this study or during participation in this study.
  2. Atrial fibrillation; severe chronic heart failure (NYHA functional class III-IV or left ventricular ejection fraction ≤40% by echocardiography); or acute coronary syndrome or acute cerebrovascular event within the previous year.
  3. Secondary hypertension.
  4. Contraindications or conditions requiring caution listed in the prescribing information for the fixed-dose combination of amlodipine and valsartan, including: hypersensitivity to the active substances, other dihydropyridine derivatives, or any excipients; severe hepatic impairment, biliary cirrhosis, or cholestasis; concomitant use of aliskiren-containing medicinal products in patients with diabetes mellitus or renal impairment (eGFR <60 mL/min/1.73 m²); second or third trimester of pregnancy; severe hypotension; shock, including cardiogenic shock; left ventricular outflow tract obstruction, including hypertrophic obstructive cardiomyopathy or severe aortic stenosis; and hemodynamically unstable heart failure following acute myocardial infarction.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: COHORT
  • Time Perspectives: PROSPECTIVE

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Amlodipine/valsartan-treated cohort

Adults with grade 2-3 hypertension who have been prescribed a fixed-dose combination of amlodipine and valsartan (Agvistat®) by their treating physician as part of routine clinical practice, independently of participation in the study. Participants are observed for up to 12 weeks to assess treatment effectiveness, adherence, safety, blood pressure control, and quality of life.
Drug: Amlodipine / Valsartan

Fixed-dose combination of amlodipine and valsartan administered as part of routine clinical practice. The treatment is prescribed by the treating physician independently of study participation. The study does not assign treatment or provide the study drug. The available doses are amlodipine 5 mg/valsartan 160 mg and amlodipine 10 mg/valsartan 160 mg, administered once daily.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Proportion of participants achieving target blood pressure at 12 weeks
Time Frame: 12 weeks

Proportion of participants who achieve the target blood pressure after 12 weeks of therapy: <140/90 mmHg for the general population or <130/80 mmHg for participants at high cardiovascular risk and participants younger than 60 years.
12 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Association between treatment adherence and clinical and demographic characteristics
Time Frame: 12 weeks

Association between treatment adherence, assessed using the Morisky-Green scale, and clinical and demographic characteristics of participants, including age, sex, comorbidities, and duration of hypertension.
12 weeks
Change in heart rate from baseline
Time Frame: 12 weeks

Change in heart rate from baseline during the observation period.
12 weeks
Change in alanine aminotransferase (ALT) from baseline
Time Frame: 12 weeks

Change in alanine aminotransferase (ALT) level from baseline during the observation period.
12 weeks
Change in aspartate aminotransferase (AST) from baseline
Time Frame: 12 weeks

Change in aspartate aminotransferase (AST) level from baseline during the observation period.
12 weeks
Change in serum creatinine from baseline
Time Frame: 12 weeks

Change in serum creatinine level from baseline during the observation period.
12 weeks
Change in blood glucose from baseline
Time Frame: 12 weeks

Change in blood glucose level from baseline during the observation period.
12 weeks
Change in low-density lipoprotein cholesterol from baseline
Time Frame: 12 weeks

Change in low-density lipoprotein cholesterol (LDL-C) level from baseline during the observation period.
12 weeks
Change in body mass index from baseline
Time Frame: 12 weeks

Change in body mass index (BMI) from baseline during the observation period.
12 weeks
Change in EQ-5D quality of life score
Time Frame: 12 weeks

Change in the score of the standardized EQ-5D quality of life questionnaire during the observation period.
12 weeks
Association of clinical and demographic factors with achievement of target blood pressure
Time Frame: 12 weeks

Association of clinical and demographic factors, including diabetes mellitus, obesity, grade of hypertension, chronic heart failure, age, and sex, with achievement of target blood pressure at 12 weeks of therapy.
12 weeks
Patient satisfaction with treatment
Time Frame: 12 week

Assessment of participants' satisfaction with treatment using a 5-point Likert scale.
12 week
Frequency and characteristics of adverse drug reactions
Time Frame: 12 weeks

Frequency and characteristics of adverse drug reactions associated with the use of the fixed-dose combination of amlodipine and valsartan, identified based on the analysis of adverse reaction reports (Yellow Cards).
12 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

VIVA PHARM LLP

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 20, 2025

Primary Completion (Estimated)

September 20, 2026

Study Completion (Estimated)

November 20, 2026

Study Registration Dates

First Submitted

September 14, 2026

First Submitted That Met QC Criteria

September 24, 2026

First Posted (Actual)

September 29, 2026

Study Record Updates

Last Update Posted (Actual)

September 29, 2026

Last Update Submitted That Met QC Criteria

September 24, 2026

Last Verified

September 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • VP-01

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe